Search results for Axsome Therapeutics

Axsome Drug’s FDA Approval Unlocks New Opportunity in Alzheimer’s Agitation

Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axso...

Why Axsome Therapeutics Stock Jumped Over 20% in April

Axonics

Axonics Anonymous (not verified) Sun, 04/05/2026 - 17:00 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...

Amylyx (AMLX) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSCo-Chief Executive Officer — Justin KleeCo-Chief Executive Officer — Joshua CohenChief Commer...

Axonics

Axonics Anonymous (not verified) Sat, 05/09/2026 - 08:22 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investo...

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patient...

Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth ratesTotal net reve...

AQUESTIVE (AQST)

AQUESTIVE (AQST) Anonymous (not verified) Sun, 04/12/2026 - 05:04 field_thread_url https://cafepharma.com/boards/threads/aquestive-aqst.646620/...

Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential

Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atro...

Argenx

Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Assembly Biosciences, Inc. (ASMB) Presents at ESCMID Global 2026 - Slideshow

Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology

Acurx (ACXP) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATETuesday, May 12, 2026 at 8 a.m. ETCALL PARTICIPANTSPresident & Chief Executive Officer — David P. LuciChief Financial Officer — Robert J. Sh...

Acurx (ACXP) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATETuesday, May 12, 2026 at 8 a.m. ETCALL PARTICIPANTSPresident & Chief Executive Officer — David P. LuciChief Financial Officer — Robert J. Sh...

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study.

Director, Sales Operations

Director, Sales Operations Anonymous (not verified) Thu, 04/23/2026 - 11:13 field_thread_url https://cafepharma.com/boards/threads/director-sales-operation...

Takeda 0 for 4 against nausea and vomiting after axing another asset

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year struggles in the therapeutic area.

<![CDATA[First Patient Dosed with Azenosertib in Aspenova Phase III Trial for Treatment of Ovarian Cancer]]>

Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atro...

<![CDATA[Pharmaceutical Executive Daily: Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics]]>

Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public

After emerging from stealth last month with $175 million in funding, Korsana Biosciences has wasted no time making its way to the public markets.

Achieve (ACHV) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATETuesday, May 12, 2026 at 8:30 a.m. ETCall participantsChief Executive Officer — Andrew Goldberg, M.D.Need a quote from a Motley Fool analyst? Em...